TEST:

Archer® FusionPlex® Lymphoma

In conclusion, our findings shed light on the unique molecular complexity of PBL, unveiling its mutational landscape and potential therapeutic targets. Due to the rarity of PBL, further research with a more extensive sample size is essential to completely elucidate the mutational landscape of PBL.

We report on one of the largest series of CD56+DLBCL with detailed clinicopathological data and for the first time described genetical findings in a limited number of patients. Our results show that CD56 expression is rare, but seems to be present in prognostic favourable subtypes of DLBCL not otherwise specified (NOS) as tested by immunohistochemical or genetic profiling.

"Integrated DNA Technologies, Inc....announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer. The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and welcome more than 100 new associates globally....Transaction Details-IDT purchased Archer NGS research assays—which reported high double-digit growth since 2019—from Invitae for cash consideration of approximately $48 million, subject to certain adjustments. The transaction is structured as an asset deal and includes a license to intellectual property related to the AMP technology."

To our knowledge, these are one of the first orthotopic PDX lymphoma models generated, that can allow us to expand patients' refractory tumors in order to extensively study molecular features of them and target effective drug profiles.

We have validated an AFPLP with faster turnaround time obtained due to changes done in the library normalization step. By using our preestablish metrics, the AFPLP demonstrated high sensitivity, accuracy, reproducibility, and precision for the detection of fusion isoforms in lymphoproliferative diseases from FFPE samples. These metrics allowed us to assess fusion genes with optimal nucleotide-level resolution of fusion breakpoints, thereby minimizing false positive/negative rates.